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00627.2017.—Pulmonary hypertension (PH) has been observed in up
to 75% of infants with moderate to severe respiratory syncytial virus
(RSV) bronchiolitis and is associated with significant morbidity and
mortality in infants with congenital heart disease. The purpose of the
present study was to establish a mouse model of PH secondary to RSV
bronchiolitis that mimics the disease etiology as it occurs in infants.
Neonatal mice were infected with RSV at 5 days of age and then
reinfected 4 wk later. Serum-free medium was administered to age-
matched mice as a control. Echocardiography and right ventricular
systolic pressure (RVSP) measurements via right jugular vein cathe-
terization were conducted 5 and 6 days after the second infection,
respectively. Peripheral capillary oxygen saturation monitoring did
not indicate hypoxia at 2–4 days post-RSV infection, before reinfec-
tion, and at 2–7 days after reinfection. RSV-infected mice had signif-
icantly higher RVSP than control mice. Pulsed-wave Doppler record-
ing of the pulmonary blood flow by echocardiogram demonstrated a
significantly shortened pulmonary artery acceleration time and de-
creased pulmonary artery acceleration time-to-ejection time ratio in
RSV-infected mice. Morphometry showed that RSV-infected mice
exhibited a significantly higher pulmonary artery medial wall thick-
ness and had an increased number of muscularized pulmonary arteries
compared with control mice. These findings, confirmed by RVSP
measurements, demonstrate the development of PH in the lungs of
mice infected with RSV as neonates. This animal model can be used
to study the pathogenesis of PH secondary to RSV bronchiolitis and
to assess the effect of treatment interventions.
NEW & NOTEWORTHY This is the first mouse model of respira-
tory syncytial virus-induced pulmonary hypertension, to our knowl-
edge. This model will allow us to decipher molecular mechanisms
responsible for the pathogenesis of pulmonary hypertension second-
ary to respiratory syncytial virus bronchiolitis with the use of knock-
out and/or transgenic animals and to monitor therapeutic effects with
echocardiography.
animal model; neonatal mouse model; pulmonary hypertension; re-
spiratory syncytial virus
INTRODUCTION
Respiratory syncytial virus (RSV) is the leading cause of
bronchiolitis in young children (30). Severe RSV bronchiolitis
is known to cause mild pulmonary hypertension (PH) in
previously healthy infants (1, 15, 39). In infants with congen-
ital heart disease (CHD) and preexisting PH, severe RSV
bronchiolitis can result in the worsening of PH and has been
associated with increased risk of the patient requiring intensive
care unit (ICU) stay, mechanical ventilator support, and in-
creased mortality (5, 25, 28, 31, 45). Improvements in ICU
management, active immunoprophylaxis with palivizumab,
and advances in pulmonary vasodilators have contributed to
improvements in clinical outcomes compared with 30 yr ago
(24, 28, 29, 31). Further investigation into the pathogenesis of
RSV is still needed to ease the suffering of infants affected by
RSV bronchiolitis, particularly those with underlying CHD/
PH, as ICU admission and death from PH crisis in severe cases
still occurs (5). In infants with preexisting PH from CHD or
bronchopulmonary dysplasia, novel therapies for severe RSV
bronchiolitis must consider various mechanisms responsible
for the substantial pulmonary vascular component of this
condition (e.g., nonuniformly elevated pulmonary artery pres-
sure because of hyperinflation/atelectasis or hypoxic vasocon-
striction, ventilation-perfusion mismatch, secondary right heart
failure, etc.) (4).
Other respiratory pathogens and diseases are known to cause
secondary PH by inducing host inflammatory responses (18,
42). PH secondary to Pneumocystis pneumonia is largely a
result of the T helper (Th)1 immune response and its main
cytokine, interferon (IFN)- (43). It has been established that
type I IFN causes PH (16), and PH is a known side effect of
IFN- or IFN- therapy for diseases such as hepatitis (35). On
the other hand, PH associated with schistosomiasis involves
Th2 immune responses (19). Transgenic mice overexpressing
IL-13 (a Th2 cytokine) spontaneously develop PH by 2 mo of
age (7). Both acute RSV bronchiolitis and asthma cause in-
flammation in the airways and lower respiratory tract obstruc-
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tion through induction of Th2 immune responses, and children
with asthma have been shown to develop PH with recurrent
hypoxia and chronic inflammation (12, 14, 26, 32).
Currently, no mouse model exists to study the pathogenesis
of PH secondary to RSV bronchiolitis. A mouse model is a
useful tool to understand the pathophysiology of human dis-
eases for many reasons, including its small size, short breeding
times, and, most importantly, the ability to genetically engineer
genes to identify their roles in disease. Severe RSV infection in
human infants involves Th2-biased immune responses (3, 27).
Therefore, to model the unique pathophysiological effects that
severe RSV infection has on human infants, we used a neonatal
mouse model of RSV infection and reinfection that has been
shown to recapitulate human severe RSV disease. RSV-in-
fected mice develop PH as demonstrated by echocardiogram
and morphometry and confirmed by right ventricular (RV)
systolic pressure (RVSP) measurement. The PH induced by
RSV bronchiolitis adequately mimics what is observed clini-
cally (9, 21, 34, 50). This model will be a critical tool to
delineate the pathogenesis of PH secondary to RSV bronchi-
olitis, discover therapeutic targets, and evaluate therapeutic
interventions.
METHODS
Mice. BALB/c breeder pairs and female adult mice (6–8 wk old)
were purchased from Harlan Laboratories/Envigo (Indianapolis, IN)
and maintained under a specific, pathogen-free condition in the
Laboratory Animal Care Unit at the University of Tennessee Health
Science Center. Pups born from time-mated mice within 24 h of one
another were used for experiments. All animal protocols were pre-
pared in accordance with the Guide for the Care and Use of Labora-
tory Animals and were approved by the Institutional Animal Care and
Use Committee and Institutional Biosafety Committee of the Univer-
sity of Tennessee Health Science Center, an American Association for
the Accreditation of Laboratory Animal Care-accredited institution.
Overall protocol. Neonatal mice were infected and reinfected with
RSV as per established protocols (9, 49, 50) and analyzed for
evidence of PH (Fig. 1). The experiment was conducted using pups
(n  4–5) born on the same date and repeated with four sets of pups.
We measured peripheral capillary oxygen saturation (SpO2) daily 2–4
days after infection, before reinfection, and 2–7 days after reinfection
using a SpO2 monitoring system (Mouseox Plus, Starr Life), which
was applied to the groin area. Echocardiography was conducted at 5
days after RSV reinfection. RVSP was measured under anesthesia at
6 days after RSV reinfection (Fig. 1). In some sets of the animals,
bronchoalveolar lavage fluid (BALF) was collected by flushing 1 ml
of PBS containing 0.5% BSA at 6 days after RSV reinfection. After
euthanasia, the lungs were perfused with PBS until they were clear of
blood, gravity inflated with zinc formalin at a fluid pressure of 25 cm
as previously described (8), and then embedded in paraffin for
histological experiments. Slides with hematoxylin-eosin and Mas-
son’s trichrome staining were prepared by the University of Tennes-
see Health Science Center pathology core. Immunohistochemistry
was conducted with rabbit anti-IL-13 antibody (1:400, catalog no.
bs-0560R, Bioss Antibodies, Woburn, MA) and anti-rabbit IgG re-
agent (ImmPRESS, Vector Laboratories, Burlingame, CA). Slides
were developed with diaminobenzidine peroxidase substrate and
counterstained with hematoxylin.
RSV infection. Human RSV strain A2 was purchased from Ad-
vanced Biotechnologies (Columbia, MD). For all mouse experiments,
the virus was propagated in Vero cells (American Type Culture Collec-
tion, Manassas, VA) using serum-free medium (SFM4MegaVir, Hy-
Clone, Logan, UT) and stored at 80°C. Five-day-old pups or adults
were anesthetized with 5% isoflurane and infected intranasally with
2  105 50% tissue culture-infective dose/g body wt of RSV in 10 l
(neonates) or 50 l (adults) serum-free medium. Control mice were
sham infected with serum-free medium (9, 49).
Echocardiography. Transthoracic echocardiography was con-
ducted under general anesthesia with 2% isoflurane (30 Hz, Vevo
2100, Visualsonics, Toronto, ON, Canada). A two-dimensional para-
sternal short-axis view was obtained at the level of the aortic valve.
Pulsed-wave Doppler recording of the pulmonary blood flow was
obtained at the tip of the pulmonary valve leaflets, and pulmonary
artery acceleration time (PAAT) and ejection time (ET) were mea-
sured (44). The RV was evaluated with B-mode and M-mode at
parasternal long-axis views. The tricuspid valve was evaluated with
color Doppler to observe tricuspid regurgitation. Left ventricular (LV)
systolic function was also evaluated by measuring ejection fraction
and fractional shorting, and the estimated cardiac output was calcu-
lated. All measurements were averaged across three cardiac cycles by
one unbiased laboratory animal veterinarian echocardiographer (R. D.
Sullivan).
RVSP measurement. RVSP was measured by inserting a 1.1-Fr
microtip pressure catheter (AD Instruments, Colorado Springs, CO)
via the right jugular vein in spontaneously breathing anesthetized
mice [Avertin (250 mg/kg ip] (6). Data were recorded via the
PowerLab system and analyzed with the Chart Pro software (AD
Instruments). Lung and heart samples were removed after euthanasia.
RV hypertrophy was assessed by calculating the ratio of RV weight to
LV 	 septum (S) weight.
Measurement of muscularization and medial wall thickness. Lung
sections were immunostained with rabbit anti--smooth muscle actin
(-SMA) antibody (1:100, catalog no. ab5694, Abcam, Cambridge,
MA) and anti-rabbit IgG reagent (ImmPRESS, Vector Laboratories).
Slides were developed with diaminobenzidine peroxidase substrate
with nickel and counterstained with hematoxylin. Tissue sections
were examined by light microscopy and photographed digitally by
Aperio Scanscope scanners (Leica Biosystems). All reagents were
purchased from Vector Laboratories unless otherwise stated. To
evaluate muscularized small pulmonary arteries in the lung sections,
the number of peribronchial pulmonary arteries (diameter 
 100 m)
with positive -SMA staining were counted by a blinded investigator
in 10 random fields of view (10 magnification) To calculate medial
wall thickness (MWT) of the small muscularized arteries, four medial
walls (a, b, c, and d) and two perpendicular lumen diameters (e and f)
Fig. 1. Respiratory syncytial virus (RSV) infection protocol. Neonatal mice were infected with RSV at 5 days of age and then reinfected at 4 wk of age. Oxygen
saturation (SpO2) monitoring was performed after RSV infection and before and after RSV reinfection. Echocardiography (ECHO) was performed 5 days after
reinfection, and right ventricular systolic pressure (RVSP) was measured at 6 days after reinfection. Mice in the control group received serum-free medium on
the same schedule.
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were measured, and MWT determined using the following formula
[(a 	 b 	 c 	 d)/4]/[(e 	 f)/2] (7). These muscularized arteries were
further categorized into fully muscularized (75% of the circumfer-
ence) and partially muscularized (50–75% of the circumference).
Protein concentration in BALF. BALF samples were kept frozen at
80°C until used. Total protein concentrations in BALF were mea-
sured using Pierce BCA Protein Assay (ThermoFisher). Samples were
duplicated and measured as per the manufacturer’s protocol.
Statistics. All data are plotted as means  SE. Student’s t-tests
(unpaired, two-tailed) were conducted to compare between the groups
for hemodynamic data, RVSP, RV/LV 	 S, echocardiographic and
histological measurements, and total protein concentration in BALF
using JMP Pro (SAS, Heidelberg, Germany). Differences were con-
sidered significant if P 
 0.05.
RESULTS
SpO2 in mice after RSV reinfection does not indicate hypoxia
in mice. To establish the mouse model of PH secondary to RSV
infection, we infected 5-day-old pups with RSV and reinfected
at 4 wk after the first infection (Fig. 1). RSV infection in
neonates followed by reinfection results in increased airway
resistance after methacholine challenge, indicating airway hy-
per-reactivity similar to bronchiolitis (50). Because hypoxia
has been shown to induce PH (46), we first measured SpO2
daily during both infection and reinfection. (Fig. 2). SpO2 levels
remained higher than 95% across all days, suggesting that
RSV-infected mice were not hypoxic. The body weight of
RSV-infected mice was significantly lower than control mice
(18.6  0.7 vs. 21.7  0.7 g, P 
 0.01).
Pulmonary vascular changes after RSV reinfection. Histo-
logical analysis of the lungs from RSV-reinfected mice re-
vealed significant peribronchial and perivascular inflammation
and fibrosis compared with those of the sham-infected control
mice (Fig. 3). To evaluate muscularization and the medial
thickness of the pulmonary arteries, lung sections were immu-
nostained to localize -SMA (Fig. 4). RSV infection induced
prominent medial thickness of pulmonary arteries and caused
an increase in the number of muscularized peripheral pulmo-
nary arteries (Fig. 4, C and F). The MWT ratio of the peri-
bronchial pulmonary arteries in RSV-infected mice was sig-
nificantly increased compared with uninfected mice (9.0  1.6
vs. 15.2  3.1, P 
 0.0001; Fig. 4H). RSV also increased
muscularized peripheral pulmonary arteries, which is an indi-
cator of PH development (full muscularization, 2.7  0.8 vs.
4.0  1.0, P  0.002, Fig. 4I; partial muscularization, 1.6 
0.7 vs. 2.6  1.0, P  0.002; Fig. 4J).
Echocardiographic changes indicative of PH. Echocardiog-
raphy was performed under general anesthesia at 5 days after
reinfection. We evaluated both PAAT and ET, because short-
ened PAAT and decreased PAAT/ET was previously shown by
Thibault et al. (44) to correlate linearly with increased RVSP
by RV catheterization. To minimize the duration of anesthesia,
whole echocardiographic images were acquired and used to
evaluate PH and RV function. Pulsed-wave Doppler of pulmo-
nary artery flow was obtained at the short-axis view in all
animals (Fig. 5A) and average values of three consecutive
pulses were used. RSV-reinfected mice demonstrated signifi-
cantly shortened PAAT and decreased PAAT/ET compared
with control mice (Fig. 5, D and E). Additionally, elevated RV
pressure caused flattening of the interventricular septum in the
end-systolic period resulting in a “D-shaped” LV (Fig. 5G) in one
mouse, and another mouse developed small pericardial effusion.
There were no significant differences in heart rate, LV ejection
fraction (52.5  1.6 vs. 58.7  8.1%, n  4–5, P  0.50),
fractional shortening (26.5  1.0 vs. 31.3  5.4%, P  0.44),
cardiac output (11.7  1.2 vs. 13.0  2.3 ml/min, P  0.63),
aortic peak velocity, and aortic valve peak pressure between the
control and RSV groups (Table 1).
RVSP elevation after RSV reinfection. RVSP was measured
via right jugular vein catheterization 6 days after RSV reinfec-
tion (Fig. 6A). RVSP was significantly increased after RSV
reinfection (15.9  1.5 vs. 29.6  6.7 mmHg, P 
 0.01)
compared with the control group (Fig. 6B). RV/LV 	 S was
higher in RSV-infected mice than in control mice (0.20  0.03
vs. 0.33  0.03, P 
 0.01; Fig. 6C).
IL-13 immunohistochemistry. Formerly, our group reported
that this RSV reinfection protocol with primary infection as a
neonate caused exacerbated Th2 responses as demonstrated by
increased Th2 cells in flow cytometry and increased production
of Th2 cytokines (IL-4 and IL-13) in BALF (50). To provide
further evidence of the involvement of the Th2 immune re-
sponse, lung sections were immunostained with anti-IL-13
antibody to localize IL-13 production (Fig. 7). IL-13-express-
ing Th2 cells were observed in the perivascular region. The
airway epithelium showed positive stain with IL-13 in both
control and RSV-infected mice. IL-13 stain was positive in the
smooth muscles of both the pulmonary artery and vein in
RSV-infected mice (Fig. 7).
Protein concentration in BALF. To investigate endothelial
permeability in this mouse model, BALF samples were col-
lected at 6 days after RSV reinfection, and total protein levels
were measured. There was no significant difference between
control and RSV-infected mice (0.4  0.013 vs. 0.38  0.02,
P  0.2).
DISCUSSION
Our results demonstrate that neonatal mice infected with
RSV and reinfected with RSV as adults develop PH. This was
evidenced by echocardiography, histological changes, and di-
rect RVSP measurement. Histological assessment of the lungs
demonstrated infiltration of inflammatory cells around pulmo-
Fig. 2. Oxygen saturation (SpO2) measurements at 2–4 days postprimary
infection (d.p.pi.), before secondary infection (pre-si.), and at 2–7 days post-
secondary infection (d.p.si.). Respiratory syncytial virus (RSV)-infected mice
(n  5 at all time points without replication) did not exhibit hypoxia.
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nary vessels and remodelling of pulmonary arteries, with
increased medial thickness and muscularization of small pe-
ripheral pulmonary arteries. RVSP measured via right jugular
vein catheterization in RSV-infected mice was elevated com-
pared with that in control mice. Flattening of the interventric-
ular septum reflecting RV pressure overload was observed in
the echocardiography. As previously reported (44), shortened
PAAT and decreased PAAT/ET measured by Doppler pulse
wave of pulmonary outflow were consistent with elevated
RVSP in our mouse model of PH secondary to RSV disease.
This is the first animal model of PH secondary to severe
RSV bronchiolitis, to our knowledge. The age of the initial
RSV infection has an important role in pathogenesis. Our
neonatal mouse (i.e., 
1 wk of the age) model resembles
human infants with severe RSV infection in terms of airway
remodeling and increased airway hypersensitivity, mucus pro-
duction, pulmonary eosinophilia, and Th2-biased immune re-
sponses (9) and has been used by us and others to study RSV
pathogenesis (10, 11, 50). Physiologically measuring the pres-
ence of PH in very young mice is challenging; therefore, these
Fig. 3. Respiratory syncytial virus (RSV) infec-
tion induced peribronchial and perivascular in-
flammation and increased medial wall thick-
ness in the pulmonary artery. Neonatal mice
were infected and reinfected with RSV. Lungs
were isolated 6 days after reinfection and em-
bedded in paraffin, and lung sections were
stained with hematoxylin and eosin (A, B, D,
and E) and trichrome (C and F). AC: control
mice; D–F: RSV-infected mice. RSV infection
induced inflammation around the bronchus
(AW), pulmonary artery (PA), and pulmonary
vein (PV) and increased medial wall thickness
in the PA. Scale bar  100 m.
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mice were reinfected with RSV as adults. This was clinically
relevant because almost all children have been infected by
RSV by 2 yr of age, and 50% of infants are reported to have
reinfection (17, 22). Interestingly, cardiac dysfunction has also
been observed in mice infected with pneumonia virus of mice
(PVM), which is similar to RSV (13). The adult PVM mouse
model mimics severe human RSV bronchiolitis in clinical
signs and lung histopathology with high viral replication but
has less involvement of the Th2 response compared with our
mouse RSV model. Although PH was not directly measured,
Fig. 4. Respiratory syncytial virus (RSV) in-
fection induced vascular remodeling of the pul-
monary artery. Neonatal mice were infected
and reinfected with RSV at 4 wk after primary
infection. Lung tissue at 6 days postinfection
was immunostained with -smooth muscle ac-
tin. Scale bar  100 m. A–C: control mice.
D–E: RSV infection caused inflammation
around the pulmonary artery and increased the
medial thickness of pulmonary artery. F: RSV
infection caused an increase in a number of
muscularized peripheral pulmonary arteries
(arrows). G: medial wall thickness was calcu-
lated with the formula [(a 	 b 	 c 	 d)/4]/
[(e 	 f)/2] after measurements with a digital
slide scan. H: medial wall thickness in the
pulmonary artery in RSV-infected and control
mice (n  3 each). I: number of fully (75%)
muscularized pulmonary arteries per field (0.70
mm2) counted at 10 magnification. (n  3 for
each group, 10 fields/slide) J: number of par-
tially (50–75%) muscularized pulmonary arter-
ies per field (0.70 mm2) counted at 10 mag-
nification. (n  3 for each group, 10 fields/
slide) Values are means  SE. A two-tailed
Student’s t-test was used.
Fig. 5. Echocardiographic evaluation. Pulmonary
flow by pulsed-wave Doppler in a respiratory
syncytial virus (RSV)-infected mouse is shown. A:
parasternal short-axis view (RSV). Blue color in-
dicates pulmonary artery flow. B: control mice; C:
RSV-infected mice. Pulmonary artery accelerating
time (PAAT) and ejection time (ET) were mea-
sured. RSV infection significantly shortened
PAAT. D and E: pulmonary pulsed-wave Doppler
measurements. RSV-infected mice had signifi-
cantly shortened PAAT and a reduced PAAT-
to-ET ratio, compatible with pulmonary hyperten-
sion. Values are means  SE; n  9 control mice
and 4 RSV-infected mice. A two-tailed Student’s
t-test was used. F and G: echocardiography of a
RSV-infected mouse at the short-axis view. F:
control mice; G: RSV-infected mice. The end-
systolic phase is shown. Interventricular septum
flatting [the left ventricle (LV) is “D-shaped” as
the septum is pushed toward the LV] was ob-
served. RV, right ventricle.
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mice infected with PVM exhibited both right- and left-sided
cardiac dysfunction as detected by cardiac MRI. There was no
evidence of direct virus-induced myocardial injury, and the
authors concluded that cardiac dysfunction was related to
severe lung injury (2). The PH observed in our model could be
also from severe lung injury or severe inflammation around
pulmonary arteries and veins. In our mouse model, LV systolic
function evaluated by echocardiography did not demonstrate
signs of dysfunction.
The pathogenesis of PH secondary to RSV bronchiolitis is
likely multifactorial. However, our group previously published
that this RSV reinfection protocol in neonatal mice induces an
exaggerated pulmonary Th2 immune response upon reinfection
(50). Flow cytometry of the lung cells isolated from RSV-
infected mice showed an increase in Th2 (IL-4-expressing
Cd4	) cells (50). BALF from RSV-infected mice revealed
eosinophil recruitment to the lung and increased Th2 cytokine
(IL-4 and IL-13) production (50). IL-13-positive stains in the
pulmonary artery and vein would strongly indicate the involve-
ment of the Th2 response in the development of PH. Further-
more, RSV-induced lower respiratory tract obstruction can
cause air trapping in the lungs, and a hyperinflated lung is
associated with increased pulmonary vascular resistance, espe-
cially in small pulmonary arteries, which can contribute to the
development of PH (47). Increased mucus production with
RSV bronchiolitis would obstruct the lower airway, and the
resulting atelectasis and decreased lung volume is also associ-
ated with an increase in pulmonary vascular resistance (47).
Mild hypoxia secondary to interstitial lung edema and low
ventilation will cause hypoxic vasoconstriction (47). Chronic
hypoxia will induce pulmonary vasoconstriction and vascular
remodeling and is widely used to induce PH in rodent models
(36, 41). Our model did not cause hypoxia as evidenced by
SpO2 monitoring after RSV primary infection and secondary
infection (Fig. 2). Hypoxia-inducible factor-1 is activated in
Table 1. Hemodynamic data of the LV during echocardiogram
Control Respiratory Syncytial Virus Infection P Value
Number of mice/group 5 4
Heart rate, beats/min 381.8  17.6 380.5  19.5 0.96
LV ejection fraction, % 52.5  1.6 58.7  8.1 0.50
LV fractional shortening, % 26.5  1.0 31.3  5.4 0.44
Cardiac output, ml/min 11.7  1.2 13.0  2.3 0.63
Aorta peak velocity, mm/s 997.8  97.7 1,000.6  104.8 0.98
Aortic valve peak velocity, mm/s 4.1  0.8 4.1  0.9 0.99
Values are means  SE. A two-tailed Student’s t-test was used. LV, left ventricle.
Fig. 6. Respiratory syncytial virus (RSV) infection in-
duced elevated right ventricular (RV) systolic pressure
(RVSP) and a higher RV-to-left ventricle 	 septum
(LV 	 S) ratio. Neonatal mice were infected and rein-
fected with RSV. A: RVSP was measured 6 days after
reinfection via right jugular vein catheterization under
spontaneous breathing. Tracings show RVSP for control
and RSV-infected mice. B: RSV induced higher RVSP
with individual data points (n  9, two-tailed t-test, P 

0.01). C: the RV-to-LV 	 S ratio at 6 days after reinfec-
tion (n  9 control mice and 10 for RSV-infected mice,
two-tailed Student’s t-test, P 
 0.01). Values are
means  SE *P 
 0.01.
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RSV infection in vitro and in a murine in vivo model, but in
these cases, the activation of hypoxia-inducible factor-1 is
independent of systemic hypoxia (20). Although other viruses
have been shown to induce PH in children secondary to lower
respiratory tract infection, RSV infection is the most cited (15,
33, 48). Inflammation may play a key role in the development
of PH in children with RSV bronchiolitis. Evidence for this
exists in lung specimens from fatal cases of human RSV,
which show bronchovascular inflammation centered on the
pulmonary arteries in the smallest airways (23).
There are several limitations in our experiments. First,
PAAT and ET measurements were performed by only one
“blinded” investigator; although this is done clinically, this
could result in a single reader error. Second, in humans, it is
known that RSV-induced PH resolves with bronchiolitis (39),
but we did not gather long-term followup data on our mice and
cannot address the reversibility of PH in our model. Third, this
is a mouse model of human RSV and mice are semipermissive
to RSV; thus, our data may underestimate the contribution of
RSV-induced disease to PH. Endothelial injury may also play
a role; however, we failed to detect endothelial injury 6 days
after secondary infection. Because we only assayed for endo-
thelial leak and only at one time point, it remains possible that
this occurs earlier in disease. Finally, we know that our
neonatal mouse model of RSV induces long-term airway re-
modeling and lung function changes consistent with asthma,
similar to what is observed in humans (37, 38, 40). Thus, our
model may resemble PH secondary to chronic wheezing/
asthma triggered by viral infection.
In summary, PH is observed secondary to severe RSV
bronchiolitis in humans and mice; our extensive data, pre-
sented elsewhere, of Th2 involvement in RSV pathogenesis in
this neonatal mouse model suggest a role for Th2 immune
responses in the development of PH. Studies are currently
underway to elucidate the role and mechanism of Th2 immune
responses in the development of PH secondary to RSV infec-
tion. Our mouse model of PH secondary to RSV infection,
developed here, allows us and others to explore molecular
mechanisms responsible for PH and test therapeutics and/or
treatment strategies to improve patient outcomes.
In conclusion, we have established the first mouse model of
PH secondary to RSV bronchiolitis. PH was confirmed in this
mouse model by RV pressure measurement, histopathology,
morphometry, and echocardiography. This mouse model of
RSV mimics the human disease in terms of airway hypersen-
sitivity, pulmonary eosinophilia, mucus production, and Th2-
biased immune reaction. Considering the presence of PH is a
prognostic factor for prolonged hospitalization in children with
RSV bronchiolitis, identifying the mechanisms responsible for
PH is of great importance and our mouse model will be a
valuable clinically relevant research tool.
ACKNOWLEDGMENTS
We thank members of Dr. Cormier’s laboratory for technical advice and
support, Dr. James West and Dr. West’s laboratory for providing the surgical
training for right ventricular systolic pressure, and Dr. Dennis Black for critical
review of the protocol. D. Kimura is a pediatric intensivist in pediatric
intensive care unit (ICU) and cardiac ICU in Le Bonheur Children’s Hospital,
Memphis, TN.
GRANTS
This work was conducted in the Children’s Foundation Research Institute in
Le Bonheur Children’s Hospital. This work was supported by Le Bonheur
Foundation Grant 641003 (to D. Kimura) and by National Institute of Allergy
and Infectious Diseases Grant R01-AI-090059 (to S. Cormier).
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
AUTHOR CONTRIBUTIONS
D.K. and S.A.C. conceived and designed research; D.K., J.S., S.J., I.M.,
L.D.V., R.D.S., S.M., D.Y., and S.A.C. performed experiments; D.K. analyzed
data; D.K., J.S., S.J., I.M., L.D.V., R.D.S., S.M., D.Y., and S.A.C. interpreted
results of experiments; D.K. prepared figures; D.K. drafted manuscript; D.K.,
J.S., S.J., I.M., L.D.V., R.D.S., S.M., D.Y., and S.A.C. edited and revised
manuscript; D.K., J.S., S.J., I.M., L.D.V., R.D.S., S.M., D.Y., and S.A.C.
approved final version of manuscript.
Fig. 7. Respiratory syncytial virus (RSV) induced IL-13
production in the lung. Immunohistochemistry was con-
ducted to localize IL-13 in lung sections from control mice
and RSV-infected mice. Some of the perivascular inflam-
matory cells expressed IL-13 in RSV-infected mice. Vas-
cular smooth muscles in the pulmonary artery (PA) and
pulmonary vein (PV) showed IL-13-positive stain in RSV-
infected mice. Scale bar  100 m.
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